, antimicrobial (Prachayasittikul et al. 2008; Salleh et al. 2012; Zhu et al. 2011; Darabpour et al. 2011), apoptotic and antiapoptotic (Mishra and Kumar 2009; Ogata et al. 2010; Lu et al. 2009 ), hypolipidemic (Ansarullah et al. 2009; Amran et al. 2012; Ikewuchi 2012a) , antidiabetic (Zardooz et al., 2012; Ikewuchi 2012b) , antitumor (Guo and Wang 2009; Khalil et al. 2008; Zeeshan et al. 2012; Tian et al. 2012; Park 2012) , anticonvulsant (Bhat et al. 2012a, b) , antiarrhythmic (Jahanbakhsh et al. 2012; Esmailidehaj et al. 2012) and anti-inflammatory (Motavallian-Naeini et al. 2012; Kamarudin et al. 2012; Su et al. 2011) substances.
We, at the Archives of Toxicology, receive numerous contributions from scientists whose research focus on the effects of natural compounds. Unfortunately, a relatively high fraction of these manuscripts is rejected by our board of reviewers. This prompted the editors, in the current Editorial, to communicate their criteria for evaluation-which are of course open for comments and discussion. Many of the several hundred studies which were turned down for publication have all used a similar approach. They usually begin by describing how various plant extracts are acquired, without any further characterization of the extracts themselves. Nevertheless, these extracts are added to cells with and without a toxic compound, in an attempt to demonstrate some protective effect. Such studies are usually rejected, because the compounds in the extracts responsible for the protective effect remain unidentified. Therefore, to increase the chance of acceptance, we propose that the submitted studies fulfil the following criteria:
• Bioactive compounds from plant extracts that have been isolated should be identified and their efficiency demonstrated.
In the 1990s, the pharmaceutical industry introduced robots that could synthesize thousands of different small molecules in a very short time. Soon, compound libraries with millions of combinatorially produced substances became available. However, despite these impressive numbers, the results were disappointing. Almost all of the produced substances were biologically irrelevant. In addition, the boom in substance research yielded no progress in drug development. This failure led to a shift in strategy. Many groups subsequently chose to design their compound libraries based on small biologically active molecules found naturally in plants, animals and microorganisms. The obvious advantage of this strategy was the millions of years of evolution that went into optimizing how these natural compounds interact with cells and organisms, for example as messengers or for defence. It is not surprising that many of the currently used drugs, such as taxanes, digitalis, morphine or salicylic acid, have been derived from nature.
Currently, enormous efforts are placed on analysing plant extracts for possible medical applications (Gebhardt 2000; Smith et al. 2013; Katalinic et al. 2006; Wagner 2011; Radojevic et al. 2012; Vasic et al. 2012; Onocha et al. 2011) . Examples are hepatotropic (Kheir Eldin et al. 2008; Young et al. 2007; Jain et al. 2012; Eidi et al. 2012; Ikewuchi et al. 2011a, b; Godoy 2011) , neurotropic (Qu et al. 2012; van Thriel 2011) and nephrotropic (Venkatanarayana et al. 2012 ) compounds, as well as antioxidative (Prachayasittikul et al. 2009; Lee et al. 2007 • Analytical data should be presented which characterize/ identify the material that has actually been tested.
• Bioactivity is demonstrated in well-characterized in vitro systems (including positive control compounds) and also in animal models in vivo.
• There are many cases where medical plants may exert therapeutic effects due to interactions with several bioactive compounds. Contributions demonstrating such interactions would be more favourably reviewed.
The editors hope that by outlining their criteria, the decision-making process becomes more transparent to scientists in this important area of research. 
